This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidneydisease (ESKD) on dialysis. However, the evidence on the benefits of ARNI in HF patients with end-stage kidneydisease (ESKD) undergoing dialysis is limited.
Patients with heart failure and mildly reduced or preservedejectionfraction (HFmrEF/HFpEF) have a high risk of developing LRTI. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide. Cox regression was used to study the effect of empagliflozin on incident LRTI.
live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidneydisease (CKD). 4 Approximately 6.7 Bozkurt A, et al.
4] More recently, at least at the epidemiologic level, the obesity paradox has been confirmed in both heart failure with reduced ejectionfraction (HFrEF) and heart failure with preservedejectionfraction (HFpEF), but also in those with coronary heart disease. [5, Carbone, Salvatore, et al. 2017): 451-463.
Additionally, 10% of the global population suffers from chronic kidneydisease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
49 
Let's personalize your content